Antitumor Activity of Di-n-Butyl-(2,6-Difluorobenzohydroxamato)Tin(IV) against Human Gastric Carcinoma SGC-7901 Cells via G2/M Cell Cycle Arrest and Cell Apoptosis
Di-n-butyl-(2,6-difluorobenzohydroxamato)Tin？(IV)(DBDFT), a potential antitumor agent against malignancies, exhibited high activities both in vitro and in vivo. Flow cytometric analysis showed that treatment with DBDFT against Human Gastric Carcinoma (SGC-7901) cells induced a concentration and time-dependent cell accumulation in the G2/M phase of the cell cycle with a parallel depletion of the percentage of cells in G0/G1, the cell apoptosis was observed by characteristic morphological changes and AnnexinV/PI dual-immunofluorescence staining. Fluorescence quantitative FQ- PCR and western blot results showed that G2/M-phase arrest was correlated with up-regulation of cyclin dependent kinase inhibitor p21, Chk2 and CyclinB1, whereas the expressions of other G2/M regulatory check-point protein, Cdc2, and feedback loop protein Cdc25C were obviously down-regulated in a p53-independent manner after the SGC-7901 cells were treated with DBDFT (2.5, 5.0, 7.5 μmol·L？1) compared with the control. Furthermore, the up-regulation of Bax and down-regulation of Bcl-2 as well as the activation of caspase-3 were observed, which indicated that DBDFT treatment triggered the mitochondrial apoptotic pathway with an increase of Bax/Bcl-2 ratios, resulting in mitochondrial membrane potential loss and caspase-9 activation in DBDFT treated SGC-7901 cells. In summary, the results illustrated the involvement of multiple signaling pathways targeted by DBDFT in mediating G2/M cell cycle arrest and apoptosis in SGC-7901 cells, which suggested that DBDFT might have therapeutic potential against gastric carcinoma as an effective compound.
References
[1]
Gielen M, Ma H, Bouhdid A, Dalil H, Biesemans M, et al. (1997) Di-n-butyl-tri-n- butyl- and triphenyltin dl-terebates: synthesis characterization and in vitro antitumour activity. Metal-Based Drugs 4: 193–197. doi: 10.1155/mbd.1997.193
[2]
Yin H, Ma C (1999) Progress in the study of metallic compounds on antitumor activity. Chemical Researches 4: 54–60.
[3]
Li Q, Guedes da Silva FMC, Pombeiro AJL (2004) Diorganotin(iv) derivatives of substituted benzohydroxamic acids with high antitumor activity. Chemistry: A European Journal 10: 1456–1462. doi: 10.1002/chem.200305266
[4]
Basu TS, Mizar A, Chandra AK (2008) Synthesis, crystal structures, cytotoxicity and qualitative structure-activity relationship (QSAR) of cis-bis{5-[(E)–2-(aryl)-1- diazenyl]quinolinolato} di-n-butyltin(IV) complexes, (n) Bu2Sn(L)2. J Inorg Biochem 102: 1719–1730. doi: 10.1016/j.jinorgbio.2008.05.001
[5]
Gielen M, Braz J (2003) An overview of forty years organotin chemistry developed at the free universities of Brussels ULB and VUB. Chem Soc 14: 870–877. doi: 10.1590/s0103-50532003000600003
[6]
Tabassum S, Pettinari C (2006) Organotin(IV) derivatives of L-cysteine and their in vitro anti-tumor properties. J Organomet Chem 691: 1761–1766.
[7]
Li T, Yunlan L, Rui G, Li QS (2012) Oxidative stress in di-n-butyl-di-(4-chloro- benzohydroxamato)tin (IV)-induced hepatotoxicity determined by proteomic profiles. Toxicology Letters 213: 167–173. doi: 10.1016/j.toxlet.2012.06.008
[8]
Yunlan L, Yang L, Xiaoqiang N, Liujin J, Xianmei S, et al. (1997) Synthesis and antitumor activity of a new mixed-ligand complex di-n-butyl-(4-chloro- benzohydroxamato)tin(IV) chloride. Journal of Inorganic Biochemistry 102: 1731–1735. doi: 10.1016/j.jinorgbio.2008.05.002
[9]
Hengartner MO (2000) The biochemistry of apoptosis. Nature 407: 770–776. doi: 10.1038/35037710
[10]
Zhou BB, Elledge SJ (2000) The DNA damage response: putting checkpoints in perspective. Nature 408: 433–439. doi: 10.1038/35044005
[11]
Deep G, Singh RP, Agarwal C, Kroll DJ, Agarwal R (2006) Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene 25: 1053–1069. doi: 10.1038/sj.onc.1209146
[12]
Donzelli M, Draetta GF (2003) Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep 4: 671–617. doi: 10.1038/sj.embor.embor887
[13]
Wang XW, Zhan Q, Coursen JD, O'Connor PM, Fornace AJJ, et al. (2001) GADD45 induction of a G2/M cell cycle checkpoint. Nucleic Acids Res 29: 2020–2025. doi: 10.1073/pnas.96.7.3706
[14]
Taylor WR, Stark GR (2001) Regulation of the G2/M transition by p53. Oncogene 20: 1803–1815. doi: 10.1038/sj.onc.1204252
[15]
Yu J, Guo QL, You QD, Zhao L, Gu HY, et al. (2007) Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis 28: 632–638. doi: 10.1093/carcin/bgl168
[16]
De Souza CP, Ellem KA, Gabrielli BG (2000) Centrosomal and cytoplasmic Cdc2/cyclin B1 activation precedes nuclear mitotic events. Exp Cell Res 257: 11–21. doi: 10.1006/excr.2000.4872
[17]
Sancar A, Lindsey-Boltz LA, Unsal-Kaccmaz K, Linn S (2004) Molecular mechanisms of mammalian DNA repair and DNA damage checkpoints. Annu Rev Biochem 73: 39–85. doi: 10.1146/annurev.biochem.73.011303.073723
[18]
Shi Y (2002) Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 9: 459–470. doi: 10.1016/s1097-2765(02)00482-3
[19]
Yunlan L, Jinjie L, Qingshan L (2010) Mechanisms by Which the Antitumor Compound Di-n-Butyl-Di-(4-Chlorobenzohydroxamato)？Tin(IV)Induces Apoptosis and the Mitochondrial-Mediated Signaling Pathway in Human Cancer SGC-7901 Cells. Molecular carcinagenesis 49: 566–581. doi: 10.1002/mc.20623
[20]
Ribble D, Goldstein NB, Norris DA, Shellman YG (2005) A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnology 5 article 12. doi: 10.1016/b978-0-12-405914-6.00020-2
[21]
Soini Y, Paakko P, Lehto VP (1998) Histopathological evaluation of apoptosis in cancer. American Journal of Pathology 153(4): 1041–1053. doi: 10.1016/s0002-9440(10)65649-0
[22]
Chen YL, Lin SZ, Chang JY (2006) In vitro and in vivo studies of a novel potential anticancer agent of isochaihulactone on human lung cancer A549 cells. Biochem Pharmacol 72: 308–139. doi: 10.1016/j.bcp.2006.04.031
[23]
Vazquez A, Bond EE, Levine AJ, Bond GL (2008) The genetics of the p53 pathway, apoptosis and cancer therapy. Nat RevDrug Discov 7: 979–987. doi: 10.1038/nrd2656
[24]
Ho JW, Song JZ, Leung YK (2005) Activation of p53 by specific agents in potential cancer therapy. Curr Med Chem Anticancer Agents 5: 131–135. doi: 10.2174/1568011053174819
[25]
Lew DJ, Kornbluth S (1996) Regulatory roles of cyclin dependent kinase phosphorylation in cell cycle control. Cell Biol 8: 795–804. doi: 10.1016/s0955-0674(96)80080-9
[26]
Liebermann DA, Hoffman B, Steinman RA (1995) Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene 11: 199–210.
[27]
Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497–1501. doi: 10.1126/science.282.5393.1497
[28]
Russo T, Zambrano N, Esposito F, Ammendola R, Cimino F, et al. (1995) A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J Biol Chem 270: 29386–29391. doi: 10.1074/jbc.270.49.29386
[29]
McShea A, Samuel T, Eppel JT, Galloway DA, Funk JO (2000) Identification of CIP-1-associated regulator of cyclin B (CARB), a novel p21-binding protein acting in the G2 phase of the cell cycle. J Biol Chem 275: 23181–23186. doi: 10.1074/jbc.m001772200
[30]
Lian F, Bhuiyan M, Li YW, Wall N, Kraut M, et al. (1998) Genistein-induced G2/M arrest, p21WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr Cancer 31: 184–191. doi: 10.1080/01635589809514701
[31]
Bulavin DV, Higashimoto Y, Popoff IJ, Gaarde WA, Basrur V, et al. (2001) Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature (Lond) 411: 102–107. doi: 10.1038/35075107
[32]
Shin SY, Yong Y, Kim CG, Lee YH, Lim Y (2010) Deoxypodophyllotoxin induces G2/M cell cycle arrest and apoptosis in HeLa cells. Cancer Lett 287: 231–239. doi: 10.1016/j.canlet.2009.06.019
[33]
Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497–1501. doi: 10.1126/science.282.5393.1497
[34]
O'Connell MJ, Walworth NC, Carr AM (2000) The G2-phase DNA-damage checkpoint. Trends Cell Biol 10: 296–303. doi: 10.1016/s0962-8924(00)01773-6
[35]
Adams JM, Cory S (1998) The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322–1326. doi: 10.1126/science.281.5381.1322
[36]
Grivicich I, Regner A, da Rocha AB, Grass LB, Alves PA (2005) Irinotecan/5-fluorou- racil combination induces alterations in mitochondrial membrane potential and caspases on colon cancer cell lines. Oncol Res 15: 385–392.
[37]
Shang XM, Wu J, Li QS (2008) The preliminary structure-activity relationship of organotin (IV) anticancer compounds with arylhydroxamates. Science in China series B: Chemistry 38(5): 429–440.
